Butoxamine is a selective antagonist of the beta2 adrenergic receptor. It was discovered in laboratories of Farbwerke Hoechst. Administration of 25-50 mg subcutaneously or 50-150 mg orally induced mescaline syndrome, disorders of consciousness and a psychotic episode with amnesia. At an oral dose of 5 mg, butoxamine inhibited metabolic changes induced by fasting and administration of catecholamines. Butoxamine was not developed further and is mainly used in biomedical research to study the functional role of beta2 receptors.